ACHV · Achieve Life Sciences, Inc. · Financials
$6.51
+0.00 (+0.00%)
At close · Oct 21
Return incl. dividend (before tax)
Market Cap
$675.04M
Shares
102.90M
Volume · Oct 21
2.47M
Avg daily vol (3M)
1.44M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$0
FY2019
Net Income
-$54.65M
-37.2%
FY2025
Diluted EPS
-$1.25
-0.8%
FY2025
Operating Cash Flow
-$49.47M
-66.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | $0 | $0 | — | — | — | — | — | — | — | — | — | |
| $26.42M | — | $22.82M | $15.81M | $30.08M | $23.97M | $6.88M | $9.67M | $5.87M | $3.1M | $286K | $25.11M | $46.22M | $55.32M | $39.95M | $21.55M | $18.48M | $20.21M | |
| $25.92M | — | $16.25M | $11.44M | $10.72M | $9.13M | $7.87M | $6.85M | $6.95M | $3.53M | $1.43M | $11.81M | $10.63M | $9.89M | $7.79M | $6.23M | $5.84M | $3.96M | |
| $200K | $200K | $200K | $200K | $200K | $200K | $200K | $200K | $200K | $200K | $200K | — | — | — | — | — | — | — | |
| $226K | $228K | $229K | $228K | $236K | $250K | $255K | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -$1.66M | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | $36.91M | $56.58M | $65.21M | — | — | — | — | |
| $58.28M | $54.88M | $39.07M | $27.25M | $40.8M | $33.09M | $14.75M | $16.53M | $12.81M | $6.63M | $1.71M | $36.91M | $56.58M | $65.21M | $46.08M | $27.78M | $28.36M | $28.12M | |
| $994K | $819K | $2.18M | $2.85M | $1.79M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $2.75M | $1.5M | $2.36M | $825K | $199K | $17K | $69K | $170K | $171K | $21K | $203K | $119K | $35K | $150K | $292K | $220K | $86K | $47K | |
| -$55.76M | $232K | -$758K | -$2.57M | -$1.55M | -$58K | $20K | $133K | $126K | -$7M | -$24K | $1.95M | $3.23M | $3.48M | $4.89M | $7.61M | -$839K | $117K | |
| — | -$54.65M | -$39.83M | -$29.82M | -$42.35M | -$33.15M | -$14.73M | -$16.4M | -$12.69M | -$13.63M | -$1.74M | — | — | — | -$21.1M | -$14.67M | -$15.58M | -$2.47M | |
| — | — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | $0 | $0 | — | -$3M | $3.01M | |
| -$114.04M | -$54.65M | -$39.83M | -$29.82M | -$42.35M | -$33.15M | -$14.73M | -$16.4M | -$12.69M | -$10.58M | -$1.23M | -$828K | -$26.24M | -$31.85M | -$21.1M | -$14.67M | -$12.58M | -$5.48M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -$14.67M | -$12.58M | -$5.48M | |
| -$114.13M | -$54.67M | -$39.8M | -$29.82M | -$42.35M | — | — | -$16.4M | -$12.69M | -$10.58M | -$1.23M | -$16.79M | -$26.26M | -$31.84M | -$21.1M | -$14.64M | -$12.62M | — | |
| USD/shares | -$1.50 | -$1.25 | -$1.24 | -$1.50 | -$4.00 | -$4.08 | -$5.42 | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$1.50 | -$1.25 | -$1.24 | -$1.50 | -$4.00 | -$4.08 | -$5.42 | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 43.59M | 32.07M | 19.83M | 10.59M | 8.12M | 2.72M | 412.32K | 175.51K | 23.97K | 106.15 | 1061.5 | 904.94K | 734.17K | 676.14K | 486.47K | 351.55K | — |
| shares | — | 43.59M | 32.07M | 19.83M | 10.59M | 8.12M | 2.72M | 412.32K | 175.51K | 23.97K | 106.15 | 1061.5 | 904.94K | 734.17K | 676.14K | 486.47K | 351.55K | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2026-06-30 | USD 36,000 | 10-Q filed 2026-08-11 |
| Current portion of convertible debt | 2026-06-30 | USD 7,454,000 | 10-Q filed 2026-08-11 |
| Noncurrent convertible debt | 2026-06-30 | USD 7,458,000 | 10-Q filed 2026-08-11 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Key facts
CIK
949858
CUSIP
004468500
13F (30d)
11 filings
11 filers
Visit website
Investor relations